Compare Monolithic Power Systems Inc (MPWR) vs TG Therapeutics Inc (TGTX) Price & Performance

Monolithic Power Systems (MPWR) trades at $1,386.29, down 2.78% on the day, with strong technical momentum indicated by a bullish moving average signal. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $6.50 versus $5.87, and maintains healthy profitability with a 24.5% net income margin. Recent developments include a manufacturing partnership with GlobalFoundries to scale power solutions for AI and data centers.

The outlook remains positive with 88% analyst buy ratings and a consensus price target of $1,830 representing 32% upside. Key risks include premium valuation multiples (P/E 83.58) and potential margin pressure from competitive markets. Earnings growth driven by AI infrastructure demand remains the primary catalyst for continued stock appreciation.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.